Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.
Personal financial interests (lecture honoraria, advisory boards, travel support): Amal Therapeutics, Aptitude Health, Amgen, Astellas, AstraZeneca, Beigene, BMS, Celgene, Daiichi Sankyo, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Pfizer, Roche, Sai-Med, Servier, Touch Oncology, Turning Point Therapeutics, Zymeworks
Institutional funding for research: Amgen, Astellas, Astra Zeneca, Basilea, BMS, Daiichi Sankyo, MSD, Macrogenics, Merus, Novartis, Roche, Seagen
Episode 1: Metastatic cancer patient case
Episode 2: Non-metastatic cancer patient case
Episode 2: Non-metastatic Gastroesophageal Cancers
Episode 3: Metastatic Gastroesophageal Cancers